• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer.

作者信息

Filetti S, Durante C, Hartl D M, Leboulleux S, Locati L D, Newbold K, Papotti M G, Berruti A

机构信息

School of Health, Unitelma Sapienza University of Rome, Rome.

Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.

出版信息

Ann Oncol. 2022 Jul;33(7):674-684. doi: 10.1016/j.annonc.2022.04.009. Epub 2022 Apr 28.

DOI:10.1016/j.annonc.2022.04.009
PMID:35491008
Abstract
摘要

相似文献

1
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer.欧洲肿瘤内科学会（ESMO）关于晚期甲状腺癌全身治疗应用的临床实践指南更新
Ann Oncol. 2022 Jul;33(7):674-684. doi: 10.1016/j.annonc.2022.04.009. Epub 2022 Apr 28.
2
[Cytokeratin expression of benign and malignant epithelial thyroid gland tumors. An immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies].[甲状腺良恶性上皮性肿瘤的细胞角蛋白表达。应用8种不同单克隆细胞角蛋白抗体对154例肿瘤进行的免疫组织学研究]
Pathologe. 1996 Nov;17(6):425-32. doi: 10.1007/s002920050181.
3
[Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies].[分子靶向治疗时代甲状腺癌的治疗进展]
Bull Cancer. 2009 Jan;96(1):95-101. doi: 10.1684/bdc.2008.0798.
4
Risk Patterns of Distant Metastases in Follicular, Papillary and Medullary Thyroid Cancer.滤泡状癌、乳头状癌和髓样甲状腺癌远处转移的风险模式
Horm Metab Res. 2022 Jan;54(1):7-11. doi: 10.1055/a-1668-0094. Epub 2021 Nov 10.
5
Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group.1996年在德国接受治疗的原发性甲状腺分化癌患者的护理模式。美国和德国甲状腺癌研究小组。
Cancer. 2000 Jul 1;89(1):192-201. doi: 10.1002/1097-0142(20000701)89:1<192::aid-cncr26>3.0.co;2-7.
6
In search of a real "targeted" therapy for thyroid cancer.寻找甲状腺癌真正的“靶向”治疗方法。
Clin Cancer Res. 2012 Apr 1;18(7):1827-9. doi: 10.1158/1078-0432.CCR-12-0153. Epub 2012 Mar 26.
7
Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium.
Horm Metab Res. 2008 Mar;40(3):210-3. doi: 10.1055/s-2008-1046781.
8
A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns].一份关于1985年至1995年在美国治疗的53856例甲状腺癌病例的国家癌症数据库报告[见评论]。
Cancer. 1998 Dec 15;83(12):2638-48. doi: 10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1.
9
[One case in which papillary thyroid carcinoma and papillary carcinoma occur on the same side].甲状腺乳头状癌和乳头状癌发生在同一侧的1例病例
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016 Mar 20;30(6):499-500. doi: 10.13201/j.issn.1001-1781.2016.06.022.
10
Overview of the 2022 WHO Classification of Thyroid Neoplasms.2022 年世卫组织甲状腺肿瘤分类概述。
Endocr Pathol. 2022 Mar;33(1):27-63. doi: 10.1007/s12022-022-09707-3. Epub 2022 Mar 14.

引用本文的文献

1
Diagnostic Evaluation of Anaplastic Thyroid Carcinoma in Core Biopsy Specimens: Morphologic, Immunohistochemical, Molecular, and Therapeutic Considerations.粗针活检标本中未分化甲状腺癌的诊断评估：形态学、免疫组织化学、分子及治疗方面的考量
Endocr Pathol. 2025 Sep 4;36(1):32. doi: 10.1007/s12022-025-09876-x.
2
ANTP-SmacN7 enhances radiosensitivity in TPC-1 cells through XIAP-mediated activation of apoptotic protein.ANTP-SmacN7通过XIAP介导的凋亡蛋白激活增强TPC-1细胞的放射敏感性。
Sci Rep. 2025 Jul 16;15(1):25779. doi: 10.1038/s41598-025-11131-6.
3
Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study.
参加美国临床肿瘤学会（ASCO）TAPUR研究的不同人群中可靶向基因组改变的患病率。
NPJ Precis Oncol. 2025 Jul 3;9(1):222. doi: 10.1038/s41698-025-00962-1.
4
Associations between pathological features and radioactive iodine-refractory recurrent papillary thyroid carcinoma: with mutation analysis using recurrent samples.病理特征与放射性碘难治性复发性乳头状甲状腺癌之间的关联：基于复发性样本的突变分析
BMC Endocr Disord. 2025 May 20;25(1):134. doi: 10.1186/s12902-025-01954-9.
5
Systemic therapies for medullary thyroid carcinoma: state of the art.甲状腺髓样癌的全身治疗：最新进展
Ther Adv Endocrinol Metab. 2025 May 11;16:20420188251336091. doi: 10.1177/20420188251336091. eCollection 2025.
6
Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study).性别对乐伐替尼治疗的放射性碘难治性分化型甲状腺癌患者安全性和疗效的影响（GISEL研究）
Eur Thyroid J. 2025 Apr 23;14(2). doi: 10.1530/ETJ-24-0386. Print 2025 Apr 1.
7
Genomic testing for RET in the clinic: UK and global perspective.临床中RET基因检测：英国及全球视角
Endocr Relat Cancer. 2025 Apr 15;32(5). doi: 10.1530/ERC-24-0230. Print 2025 May 1.
8
Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer.多激酶和高选择性激酶抑制剂在甲状腺癌患者新辅助治疗中的应用
Explor Target Antitumor Ther. 2025 Feb 13;6:1002291. doi: 10.37349/etat.2025.1002291. eCollection 2025.
9
Reflective analysis on the current I adjuvant therapy indications in intermediate- and high-risk differentiated thyroid cancer.关于中高危分化型甲状腺癌当前辅助治疗指征的反思分析
Eur J Nucl Med Mol Imaging. 2025 Mar 8. doi: 10.1007/s00259-025-07153-x.
10
BRAF mutation is associated with better prognoses in radioactive iodine refractory thyroid cancer patients treated with multi-kinase inhibitors: a retrospective analysis of registered clinical trials.BRAF突变与接受多激酶抑制剂治疗的放射性碘难治性甲状腺癌患者的较好预后相关：一项注册临床试验的回顾性分析
Thyroid Res. 2025 Feb 10;18(1):5. doi: 10.1186/s13044-025-00223-0.